Aim: Type collagen abundantly exists in the cardiovascular system, including the aorta and heart. We prospectively investigated whether serum levels of aminoterminal propeptide of type procollagen (P NP), a circulating biomarker of cardiovascular fibrosis, could predict cardiovascular events in patients undergoing hemodialysis.
Introduction
Fibrillar collagen is synthesized in cardiac fibroblasts as a procollagen 1) . The myocardium and coronary artery comprise type and collagen as major fibrillar collagens. Increased collagen turnover plays an important role in determining the functional properties of the arterial vasculature and ventricular myocardium 2) , and that in the coronary artery contributes to coronary intimal thickening and progression of coroCopyright©2019 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
long-term cardiovascular events, even in the absence of heart failure or dilated cardiomyopathy. In the present study, we aimed to prospectively investigate whether the serum levels of P NP could predict the long-term cardiovascular events in patients without apparent heart failure or cardiomyopathy undergoing maintenance hemodialysis.
Methods

Patients
Fig. 1 is the flow diagram of subject recruitment. Patients with end-stage kidney disease undergoing maintenance hemodialysis for more than 1 year in Toujinkai Hospital, Japan, at the point of January 1, 2005, who met the inclusion criteria, were eligible for this study. Of the 384 patients undergoing hemodialysis, 302 met the eligibility criteria. Exclusion criteria were as follows: a history of coronary events and/or interventions; congestive heart failure of New York Heart Association grades to ; moderate or worse valvular heart disease (aortic or mitral valvular areas ≤ 1.5 cm 2 for aortic or mitral stenosis, and Sellers grades or for aortic or mitral regurgitation); permanent pacemaker implantation; idiopathic hypertrophic or dilated cardiomyopathy; chronic obstructive pulmonary disease; malignancy; and acute hepatitis, chronic hepatitis, liver cirrhosis, or dial fibrosis in humans, only P NP and the carboxyterminal propeptide of type procollagen (C PC), formed during the extracellular conversion of type procollagen into mature fibril-forming type collagen, have been shown to be associated with myocardial fibrosis [5] [6] [7] [8] .
Aim
Left ventricular hypertrophy (LVH) and arterial stiffness, which significantly contribute to the occurrence of cardiovascular events, are the common findings in patients undergoing hemodialysis 9, 10) . Fibrosis in the cardiovascular system is involved in remodeling of the heart and vascular system, and it plays an important role in the genesis of LVH and arterial stiffness. Circulating P NP, a biomarker of type collagen synthesis, has been shown to predict prognosis in patients with heart failure and ischemic heart disease 11, 12) or in the general population with idiopathic dilated cardiomyopathy 5, 6, 13) . In a previous study, the extent of myocardial fibrosis was associated with mortality in patients with dilated cardiomyopathy and heart failure undergoing hemodialysis 14) . Because patients undergoing hemodialysis have higher cardiovascular risks such as LVH or aortic stiffness than the general population, increased fibrosis in the cardiovascular system may cause 
Echocardiography
All patients underwent two-dimensionally guided echocardiography using a single ultrasonographic recorder (UF-8800, Fukuda Denshi, Tokyo, Japan) on a midweek non-dialysis day within 1 month after the enrollment. LV ejection fraction (LVEF) was quantified using the modified Simpson rule, and LV mass was normalized to body surface area, and is described herein as left ventricular mass index.
Endpoint
All 244 patients were followed up at Toujinkai Hospital. The endpoint was cardiovascular events: cardiovascular deaths, including death caused by acute myocardial infarction (AMI) or congestive heart failure, and sudden cardiac death (SCD); coronary interventions, including percutaneous coronary intervention or coronary artery bypass grafting; vasospastic angina identified by coronary angiography; malignant arrhythmias such as ventricular tachycardia or fibrillation; bradycardia needing permanent pacemaker implantation; congestive heart failure needing hospitalization; cardiac valvular disease needing operation; aortic aneurysm including rupture or dissection; or peripheral artery disease needing vascular bypass or leg amputation. SCD was defined as death within 24 h of the time that the victim was last seen alive in a normal state of health, and cardiac diseases such as malignant arrhythmias or acute coronary syndrome were considered the most frequent causes of death. Cerebrovascular accidents were ruled out by post-mortem examinations. Cardiologists in Toujinkai Hospital or Kyoto Second Red Cross Hospital diagnosed cardiac-derived death, and they did not know about the study protocol at the point of diagnosis.
Statistical Analysis
Continuous values were expressed as the median SE. Continuous variables were compared using MannWhitney U test. Categorical data were analyzed using the Chi-square test. Receiver operating characteristic analysis was performed to define the threshold of P NP for cardiovascular events; thresholds were obtained from minimal false positive and false negative results, that is, by minimizing the expression (1 specificity) 2 (1 sensitivity) 2 . The associations of clinical factors with cardiovascular events were analyzed using Cox hazard model. Stepwise Cox hazard analysis was performed among significant (P 0.05) factors in univariate analysis. Cardiovascular event-free survival rates were assessed using the Kaplan -Meier method and the log-rank test. A P value of 0.05 was considered statistically significant. Individuals who were blinded to all personal information about the patients statisticarrier of hepatitis virus, or laboratory disorder of liver function by unknown origin. Of 302 patients who met the eligibility criteria, 58 were excluded based on the exclusion criteria. Consequently, 244 patients (men, 126; women, 118; mean age, 64 11 years; dialysis duration, 11.5 7.8 years) were enrolled in the study from January 1 to 31, 2005, and followed through January 31, 2011. Blood pressure was measured hourly during dialysis using a mercury sphygmomanometer; for study purposes, blood pressure was determined as the mean of the measurements obtained at the beginning of eight consecutive midweek hemodialysis sessions before enrollment. Histories of cigarette smoking and alcohol consumption were determined by a questionnaire. A smoking habit was defined as smoking 10 or more cigarettes per week. Alcohol consumption was defined as alcohol intake three times or more per week. The Ethics Committee for Human Research of Toujinkai Hospital approved this study. All patients provided written informed consent to all procedures associated with the study before participation. The study was performed in accordance with the principles of the Declaration of Helsinki and registered in the ClinicalTrials.gov (https://clinicaltrials.gov/): protocol identifier, NCT03391128.
Measurement of P NP
Blood was collected for determination of serum P NP concentration just before starting the first hemodialysis session of the week after the enrollment. Serum P NP was determined by immunoradiometric assay (RIA-gnost P P c.t., CIS Bio International, Saclay, France). The intra-and interassay coefficients of variation for this assay were 1.4% -2.9% and 2.5% -3.1%, respectively.
Biochemical and Hematological Determinations
Other blood samples were collected at the same hemodialysis sessions for the sampling of P NP. We measured blood hemoglobin levels; serum concentrations of aspartate aminotransferase, alanine aminotransferase, -glutamyl transferase, total cholesterol, highdensity lipoprotein cholesterol, triglyceride, albumin, calcium, inorganic phosphorus, intact parathyroid hormone, 2 microglobulin, high-sensitivity C-reactive protein, or hemoglobin A1c; and plasma concentrations of B-type natriuretic peptide (BNP) or aldosterone. Plasma BNP and aldosterone concentrations were measured using commercially available immunoradiometric assay kits (Shionoria BNP kit, Shionogi, Osaka Japan; SPACS-S Aldosterone kit, Dai-ichi Radioisotope, Tokyo, Japan). The intra-and interassay coefficients of variation for determining BNP concentration were 5.3% and 5.9%, respectively. implantation (n 7:5 sick sinus syndrome and 2 complete atrioventricular block), dissecting aortic aneurysm (n 2), aortic valvular stenosis needing valve replacement (n 1), peripheral artery disease needing bypass surgery (n 1), and leg amputation (n 1). One of the two patients with dissecting aneurysm died immediately after the diagnosis.
Serum P NP
Serum P NP concentrations were distributed between 0.30 and 9.50 U/mL, with a median of 1.40 0.08 U/mL for all subjects (Fig. 2) . To evaluate reproducibility of serum P NP levels in this population, we remeasured the serum P NP concentrations after 1 month of the first measurement in 30 of the participants; serum P NP concentrations (mean SD) did not differ during 1 month: 1.83 1.02 U/mL versus 1.85 1.03 U/mL. In the Japanese population, the reference interval for P NP in this assay kit is 0.30 -0.80 U/mL; the serum P NP concentrations of patients undergoing hemodialysis would be higher than those of normal population, as previously reported 15) . Serum P NP concentration was positively correlated with dialysis periods (r 0.46, P 0.001), serum calcally analyzed all data. All statistical analyses were performed using IBM SPSS Statistics software, version 23.
Results
All 244 patients had been followed up in Toujinkai Hospital until the endpoint was reached, or until January 31, 2011 (end of the study). During follow-up for 4.7 1.8 years, all-cause death occurred in 62 patients (25.4%), as follows: cardiovascular deaths (n 20: 14 SCD, 3 AMI deaths, 2 heart failure deaths, and 1 rupture of dissecting aortic aneurysm), malignancy (n 11), infection (n 10), cerebrovascular accidents (n 7:4 cerebral bleeding and 3 cerebral infarction), digestive system diseases (n 6), respiratory failure (n 4), liver failure (n 1), leukemia (n 1), multiple organ failure (n 1), and senility (n 1). Cardiovascular death was 31.7% of all-cause death. Cardiovascular events occurred in 78 (32%) of 244 patients, as follows: cardiac deaths (n 19), non-fatal AMI (n 1), obstructive coronary artery disease needing percutaneous coronary intervention (n 22), vasospastic angina identified by angiography (n 3), heart failure needing hospitalization (n 21), bradycardia needing pacemaker .50 U/mL, and the median value was 1.40 0.08 U/mL for all subjects. In the Japanese population, the reference interval for P NP in this assay kit is 0.30 to 0.80 U/mL; the serum P NP concentrations of patients undergoing hemodialysis would be higher than those of normal population.
Cardiovascular Events and P NP
Patients with cardiovascular events had longer dialysis duration; higher age or serum P NP concentration; and lower diastolic blood pressure, serum albumin, or intact parathyroid concentration, or administration ratio of antiplatelet drugs than those without cium concentration (r 0.24, P 0.001), calcium-inorganic phosphate product (r 0.15, P 0.017) or cardiovascular events (r 0.54, P 0.001), and inversely correlated with diabetes mellitus (r 0.17, P 0.009) or diastolic blood pressure (r 0.16, P 0.014). events with age or serum P NP concentration, and an inverse association with diastolic blood pressure or LVEF (Table 3) . Serum P NP concentration was also positively associated with cardiac death (hazard ratio, 1.32; 95% CI, 1.02 -1.70; P 0.032). In receiver operating characteristic analysis, the threshold of serum P NP concentration for cardiovascular events was de- (Table 1) . In univariate Cox hazard analysis, cardiovascular events were positively associated with age, dialysis duration, cardiothoracic ratio, or serum P NP concentration, and inversely associated with diastolic blood pressure, LVEF, or serum albumin concentration ( Table 2) . Stepwise Cox hazard analysis among these factors revealed a positive association of cardiovascular Myocardial fibrosis is of two types: focal and diffuse 26) . Focal fibrosis replaces dead cardiomyocytes and forms scars. Diffuse fibrosis occurs in the interstitial and perivascular space, and it is involved in the various pathophysiological and clinical features of chronic cardiac diseases: increased LV stiffness and diastolic dysfunction, impaired LV systolic dysfunction, arrhythmias, and impaired coronary flow reserve [27] [28] [29] [30] . In addition, increased collagen turnover is associated with the functional properties of the arterial vasculature. Increased arterial stiffness due to medial fibrosis contributes to LVH, myocardial ischemia, and microcirculatory disturbance in the heart 31) . Diffuse fibrosis in the heart and vasculature affect each other to promote the occurrence of cardiovascular events.
In the present study, SCD was the main cause of cardiac death. Sudden death occurs more frequently in patients undergoing hemodialysis compared with general population: SCD accounts for approximately onetermined as 1.75 U/mL (Fig. 3) . When patients were assigned to subgroups based on this serum P NP cutoff value, cardiovascular event-free survival rates at 5 years were lower in the subgroup of serum P NP of 1.75 U/mL or more than in that of serum P NP below 1.75 U/mL (31.9% vs 88.2%) (Fig. 4) .
Discussion
Various studies have indicated that circulating P NP levels are associated with LV remodeling induced by hypertension, myocardial infarction, heart failure 4, 5, 7, 13, [16] [17] [18] , or aortic stiffness 18, 19) and prognosis including mortality 6, 11, 12, 20, 21) . However, there are few studies showing the relationship between circulating P NP and cardiovascular events in patients undergoing hemodialysis. To the best of our knowledge, this study is the first to show the independent association of serum P NP concentration with cardiovascular event occurrence in patients undergoing hemodialysis. Because serum P NP levels are reportedly elevated in acute or chronic liver diseases and correlate positively with serum aminotransferase or bilirubin levels 22) , patients with liver disease were excluded from this study. In addition, laboratory data of serum aminotransferases were not related with serum P NP levels in the participants of our study. Because serum P NP concentrations did not change during 1 month in our study and did not vary throughout the day in the study by Saggese et al. 23) , it may be concluded that serum P NP concentrations remain stable in patients undergoing hemodialysis. The molecular weight of P NP is 42000 Da; P NP would not be removed by hemodialysis, but partly removed by hemodialysis filtration, although we had not evaluated the changes of serum P NP before and after dialysis. Because serum P NP is reportedly cleared from the blood via hepatobiliary elimination and does not depend on renal function 24, 25) , predialysis serum P NP concentrations are thought to directly indicate P NP turnover. In addition, because collagen type abundantly exists in the cardiovascular system 2, 3) , increased serum P NP levels indicating advanced turnover of collagen type may be a risk factor for cardiovascular events in this population. ening, reduced capillary density, and myocardial fibrosis are unique findings in the heart of patients undergoing hemodialysis 40, 41) ; these myocardial abnormalities can potentially cause myocardial microcirculatory disturbance. These characteristics in patients undergoing hemodialysis result in increased susceptibility of myocardial cells to reduced myocardial blood supply in patients undergoing hemodialysis than in non-dialysis patients. Advanced collagen turnover in the aorta may be involved in the early detection of myocardial ischemia based on obstructive coronary artery disease.
Not only LVH but also LV systolic function is deeply involved in the prognosis of patients undergoing hemodialysis. Previous studies have indicated that LVEF examined by echocardiography could detect the high-risk group of hemodialysis population 42, 43) . Myocardial fibrosis and myocardial ischemia are likely involved in reduced LV systolic function, as described earlier. In the present study, LVEF and serum P NP were independently associated with the occurrence of cardiovascular events. We may have to pay attention to protecting patients undergoing hemodialysis with low LVEF and high serum P NP concentration of 1.75 U/mL or more from future cardiovascular events.
This study has several limitations. The long observation duration (mean period: 4.7 years) could have introduced various biases on the results. We considered 19 sudden deaths as cardiac death, although a coronary origin was not clearly determined. We could not completely eliminate the possibility of hyperkalemia or some other cause for these deaths. The tissue and fourth of all-cause mortality in patients undergoing dialysis 32, 33) . The main cause of SCD is believed to be hemodynamic collapse due to malignant arrhythmia such as ventricular fibrillation in the setting of structural heart disease 34) . Arrhythmias were reportedly responsible for 78% of all cardiac deaths or 29% of allcause mortality in patients undergoing hemodialysis 35) . A triggering event or condition interacts with the underlying structural heart disease to produce fatal arrhythmia. LVH, the most frequent cardiac abnormality in patients undergoing dialysis 36) , causes electrical remodeling of the heart 37) , and ventricular arrhythmia is increased in patients with echocardiographically identified LVH compared with those without 38) . Advanced myocardial fibrosis, an important component of LVH, might be associated with fatal arrhythmias such as ventricular tachycardia/fibrillation via the mechanism of localized conduction disturbance and spiral reentry 39) . In addition, obstructive coronary artery disease accounted for a large percentage of cardiovascular events. Because the main fibrillar collagen in coronary plaque is type collagen, type collagen is thought not to be involved in the progression of coronary plaque 3)
. On the contrary, type collagen is the most abundant form of collagen in the aortic wall 3) ; increased collagen turnover of medial layers of the aorta decreases vascular distensibility, leading to increased arterial stiffness, as described earlier. Increased arterial stiffness contributes to causing LVH, including myocardial fibrosis 27, 28) ; it easily leads to impaired coronary blood flow 30) . In pathological studies, intramyocardial arteriolar thick- 
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Conclusion
Higher levels of circulating P NP may be associated with increased collagen turnover or fibrosis of the cardiovascular tissues, leading to sclerosis of the vascular systems and myocardial remodeling or overload. In the EPHESUS study of patients with congestive heart failure after AMI, circulating P NP levels did not correlate with cardiovascular events or mortality for a mean follow-up of 16 months 12) . On the contrary, high basal values of P NP were correlated with cardiovascular mortality in patients with chronic heart failure in the RALES study 10) . Serum P NP concentrations may be able to predict more accurately longterm cardiovascular events in chronic conditions such as heart failure or end-stage kidney disease than earlyphase events such as AMI.
